Alan Wiseman, MD
Cardiovascular Disease · Bangor, MENPI 1629049200
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (53.6%), food and beverage and education — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by CSL Behring at 53.6% of the total.
Across 6 payments — averaging $97.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$313
- Boston Scientific$149
- Shockwave Medical, Inc$86
- Merck$36
Across 390 payments — averaging $8534.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1M
- CSL Behring$1M
- Amgen$781K
- Regeneron$121K
- AstraZeneca$112K
- Janssen Research & Development, LLC$104K
- plus $143K from 5 others
What the payments were for
- Travel & lodging$31354%
- Food & beverage$23440%
- Education$366%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 1 | $313 |
| Boston Scientific | 2 | $149 |
| Shockwave Medical, Inc | 1 | $86 |
| Merck | 2 | $36 |
How this compares
$583 in reported general payments places this provider in the 70th percentile of 99 cardiovascular disease providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 37 | $43,240 |
| EntrestoSacubitril/Valsartan | 22 | $43,136 |
| JardianceEmpagliflozin | 16 | $22,808 |
| Praluent PenAlirocumab | 17 | $10,148 |
| Repatha SureclickEvolocumab | 18 | $9,773 |
| Dofetilide | 13 | $6,269 |
| Amiodarone Hcl | 29 | $1,256 |
| Rosuvastatin Calcium | 41 | $966 |
| Ezetimibe | 48 | $945 |
| SotalolSotalol Hcl | 25 | $443 |
| ClopidogrelClopidogrel Bisulfate | 31 | $387 |
| Metoprolol Succinate | 26 | $294 |
| Amlodipine Besylate | 37 | $264 |
| Indapamide | 15 | $212 |
| Lisinopril | 15 | $162 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Bangor
- Christopher LangBangor$3K
- Sverrir GunnarssonBangor$2K
- Eddy KarnabiBangor$2K
- Chae ChoiBangor$2K
- Rupert FinckeBangor$2K
- Thorarinn BjarnasonBangor$741
- Qurat Ul Ain JelaniBangor$429
- Christine RutlenBangor$364
- Peter Ver LeeBangor$327
- Jims Jean-JacquesBangor$285
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.